• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环肿瘤 DNA 监测在转移性癌症中的报告——从临床有效性到临床实用性。

Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.

机构信息

Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.

出版信息

Cancer. 2022 Jun 1;128(11):2052-2057. doi: 10.1002/cncr.34168. Epub 2022 Mar 18.

DOI:10.1002/cncr.34168
PMID:35302663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9543969/
Abstract

This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.

摘要

本述评旨在探讨循环肿瘤 DNA（ctDNA）分析所需的标准化，从而提高实体瘤转移患者中 ctDNA 监测的临床有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3279/9543969/bb56289dcaeb/CNCR-128-2052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3279/9543969/bb56289dcaeb/CNCR-128-2052-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3279/9543969/bb56289dcaeb/CNCR-128-2052-g001.jpg

相似文献

1
Reporting on circulating tumor DNA monitoring in metastatic cancer-From clinical validity to clinical utility.循环肿瘤 DNA 监测在转移性癌症中的报告——从临床有效性到临床实用性。
Cancer. 2022 Jun 1;128(11):2052-2057. doi: 10.1002/cncr.34168. Epub 2022 Mar 18.
2
Mutant Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.循环肿瘤 DNA 突变是一种用于胰腺癌监测的精确工具。
Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25.
3
Circulating cell-free tumor DNA analysis in pediatric cancers.循环肿瘤游离 DNA 分析在儿科癌症中的应用。
Mol Aspects Med. 2020 Apr;72:100819. doi: 10.1016/j.mam.2019.09.003. Epub 2019 Sep 25.
4
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.癌症患者循环肿瘤 DNA 分析：美国临床肿瘤学会和美国病理学家学会联合审查。
J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.
5
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.循环肿瘤 DNA 丰度及其在初发性转移性前列腺癌中的潜在应用。
Eur Urol. 2019 Apr;75(4):667-675. doi: 10.1016/j.eururo.2018.12.042. Epub 2019 Jan 10.
6
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.基于循环肿瘤 DNA 改变的临床和基因组分析在转移性激素敏感型和去势抵抗性前列腺癌中的应用。
EBioMedicine. 2020 Apr;54:102728. doi: 10.1016/j.ebiom.2020.102728.
7
Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.通过对患者来源的循环肿瘤细胞和肿瘤 DNA 进行下一代测序对癌症患者进行监测。
Cancer Sci. 2019 Aug;110(8):2590-2599. doi: 10.1111/cas.14092. Epub 2019 Jul 23.
8
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy.循环肿瘤 DNA 作为癌症治疗中反应和随访标志物的临床效用。
Cancer Metastasis Rev. 2020 Sep;39(3):999-1013. doi: 10.1007/s10555-020-09876-9.
9
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.对 KRAS 突变的循环肿瘤 DNA 进行纵向监测可预测胰腺癌患者的预后和治疗反应。
PLoS One. 2019 Dec 31;14(12):e0227366. doi: 10.1371/journal.pone.0227366. eCollection 2019.
10
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.血浆循环肿瘤 DNA 与转移性肾细胞癌中的克隆性造血。
Clin Genitourin Cancer. 2020 Aug;18(4):322-331.e2. doi: 10.1016/j.clgc.2019.12.018. Epub 2020 Jan 8.

引用本文的文献

1
Laboratory practices for next-generation sequencing-based circulating tumor DNA analysis: insights from a comprehensive survey in China.基于下一代测序的循环肿瘤DNA分析的实验室实践：来自中国一项全面调查的见解
Virchows Arch. 2025 Jun 25. doi: 10.1007/s00428-025-04156-9.
2
ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.基于循环肿瘤DNA（ctDNA）的液体活检揭示了早期乳腺癌患者更广泛的突变谱，以及与治疗耐药性和转移易感性相关的特征。
J Liq Biopsy. 2024 Dec 27;7:100284. doi: 10.1016/j.jlb.2024.100284. eCollection 2025 Mar.
3

本文引用的文献

1
Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer.循环肿瘤DNA升高作为转移性乳腺癌早期疾病进展的分子生物标志物
JCO Precis Oncol. 2020 Nov;4:1246-1262. doi: 10.1200/PO.20.00117.
2
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.循环肿瘤DNA预测接受PD-L1阻断或化疗的非小细胞肺癌患者的总生存期。
JCO Precis Oncol. 2021 Nov;5:827-838. doi: 10.1200/PO.21.00057.
3
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health.
A perspective review on the systematic implementation of ctDNA in phase I clinical trial drug development.
关于循环肿瘤DNA（ctDNA）在I期临床试验药物研发中的系统应用的前瞻性综述。
J Exp Clin Cancer Res. 2025 Mar 1;44(1):79. doi: 10.1186/s13046-025-03328-4.
4
Circulating Tumor DNA and [F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC.循环肿瘤DNA和[F]氟代脱氧葡萄糖正电子发射断层扫描用于晚期非小细胞肺癌患者的早期反应评估
Diagnostics (Basel). 2025 Jan 22;15(3):247. doi: 10.3390/diagnostics15030247.
5
Integration of personalised ultrasensitive ctDNA monitoring of patients with metastatic breast cancer to reduce imaging requirements.整合转移性乳腺癌患者的个性化超灵敏循环肿瘤DNA监测以减少成像需求。
Int J Cancer. 2025 Apr 15;156(8):1509-1517. doi: 10.1002/ijc.35292. Epub 2024 Dec 18.
6
Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.循环肿瘤 DNA 水平与胃肠间质瘤肿瘤体积相关：一项探索性的长期随访研究。
Mol Oncol. 2024 Nov;18(11):2658-2667. doi: 10.1002/1878-0261.13644. Epub 2024 May 24.
7
Is It Time to Expand Our Definition of "Clinical Utility"?是否到了扩大“临床实用性”定义的时候了？
Cancer Control. 2023 Jan-Dec;30:10732748231170483. doi: 10.1177/10732748231170483.
8
Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non-small Cell Lung Cancer.循环肿瘤 DNA 监测揭示了真实世界晚期非小细胞肺癌患者队列中在影像学进展前的分子进展。
Cancer Res Commun. 2022 Oct 13;2(10):1174-1187. doi: 10.1158/2767-9764.CRC-22-0258. eCollection 2022 Oct.
9
Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer.循环肿瘤DNA中的基因甲基化作为转移性结直肠癌治疗效果的早期生物标志物
Cancers (Basel). 2022 Sep 14;14(18):4459. doi: 10.3390/cancers14184459.
10
Post-Treatment Neck Dissection of Tonsillar and Base of Tongue Squamous Cell Carcinoma in the Era of PET-CT, HPV, and p16.PET-CT、HPV 和 p16 时代的扁桃体和舌根鳞状细胞癌的治疗后颈部清扫术
Viruses. 2022 Jul 30;14(8):1693. doi: 10.3390/v14081693.
通过美国国立卫生研究院基金会的竞争前合作验证 ctDNA 质量控制材料。
JCO Precis Oncol. 2021 Jun 1;5. doi: 10.1200/PO.20.00528. eCollection 2021.
4
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC.血浆 ctDNA 反应是晚期 NSCLC 治疗效果的早期标志物。
JCO Precis Oncol. 2021 Feb 17;5. doi: 10.1200/PO.20.00419. eCollection 2021.
5
Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal.循环肿瘤 DNA 的含量取决于肿瘤类型和肿瘤大小的动态变化，但不受体育锻炼、一天中的时间或最近的用餐时间的显著影响。
Cancer Genet. 2021 Aug;256-257:165-178. doi: 10.1016/j.cancergen.2021.05.014. Epub 2021 May 28.
6
Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy.基于 Pembrolizumab 的治疗方案治疗晚期 NSCLC 患者中，利用下一代基因测序进行循环肿瘤 DNA 的连续监测作为反应和生存的生物标志物。
JCO Precis Oncol. 2021 Mar 19;5. doi: 10.1200/PO.20.00321. eCollection 2021.
7
Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival.早期循环肿瘤DNA对化疗的反应。总生存的潜在替代标志物。
Eur J Cancer. 2021 May;149:128-133. doi: 10.1016/j.ejca.2021.03.006. Epub 2021 Apr 12.
8
Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.分析循环肿瘤DNA以识别可能从序贯酪氨酸激酶抑制剂治疗中获益的表皮生长因子受体阳性非小细胞肺癌患者。
Eur J Cancer. 2021 May;149:61-72. doi: 10.1016/j.ejca.2021.02.031. Epub 2021 Apr 5.
9
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).早期血浆循环肿瘤 DNA（ctDNA）变化可预测非小细胞肺癌（NSCLC）一线帕博利珠单抗治疗的反应。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001504.
10
How to use liquid biopsies to treat patients with cancer.如何利用液体活检来治疗癌症患者。
ESMO Open. 2021 Apr;6(2):100060. doi: 10.1016/j.esmoop.2021.100060. Epub 2021 Feb 26.